| 产品描述: | 6-磷酸葡萄糖酸脱氢酶抑制剂;6-phosphogluconate dehydrogenase inhibitor;100ml水可溶0.3g,不溶于一般有机溶剂。有致畸可能性。;Product Application:6-Aminonicotinamide induces apoptosis in tumor cells. It is clinically used in disseminated neoplastic disease. It also acts as 6-phosphogluconate dehydrogenase inhibitor. It aids in the treatment of psoriasis. It is used as cancer chemotherapeutic drug in animals. |
| 体内研究: |
6-Aminonicotinamide (20 mg/kg;腹腔注射;刺激时间;第 1、10 或 11 和 21 天) 单独诱导小但显著的肿瘤生长延迟 (4.3+/-0.8 天)。在 CD8F1 乳腺肿瘤模型中,先用 6-Aminonicotinamide 处理再放疗可诱导 57.0+/-3.8 天的肿瘤生长延迟。 |
| 参考文献: |
1. Cheng J, et al. TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT pathway and PPP metabolism. Nat Commun. 2020;11(1):1880. Published 2020 Apr 20. 2. Almugadam SH, et al. Influence of 6-aminonicotinamide (6AN) on Leishmania promastigotes evaluated by metabolomics: Beyond the pentose phosphate pathway. Chem Biol Interact. 2018;294:167-177. 3. Tsouko E, et al. Regulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growth. Oncogenesis. 2014;3(5):e103. Published 2014 May 26. 4. Koutcher JA, et al. Effect of 6-aminonicotinamide on the pentose phosphate pathway: 31P NMR and tumor growth delay studies. Magn Reson Med. 1996;36(6):887-892. |
| 保存条件: |
避光,-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
7.292 ml |
36.459 ml |
72.918 ml |
| 5 mM |
1.458 ml |
7.292 ml |
14.584 ml |
| 10 mM |
0.729 ml |
3.646 ml |
7.292 ml |
| 50 mM |
0.146 ml |
0.729 ml |
1.458 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |